New cancer vaccine combo aims to outperform standard treatment in major trial
NCT ID NCT06790966
Summary
This large, late-stage trial is testing whether adding an experimental immunotherapy called PDS0101 to the standard drug pembrolizumab (Keytruda) helps people with advanced HPV-positive head and neck cancer live longer. The study will enroll about 351 adults whose cancer has returned or spread and who have not yet received treatment for this advanced stage. Researchers will directly compare the survival and tumor response of patients receiving the combination versus the standard drug alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University - Winship Cancer Institute (WCI)
Atlanta, Georgia, 30322, United States
-
Florida Cancer Affiliates - Ocala Oncology
Ocala, Florida, 34474, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19103, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Marin Cancer Care
Greenbrae, California, 94904, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29407, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40202, United States
-
Penn State Health
Hershey, Pennsylvania, 17033, United States
-
SCRI - Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
Texas Oncology
Austin, Texas, 78705, United States
-
Texas Oncology-Northeast Texas
Tyler, Texas, 75702, United States
-
The Ohio State University- James Cancer Hospital
Columbus, Ohio, 43210, United States
-
UT Health San Antonio
San Antonio, Texas, 78229, United States
-
University of California, Orange
Orange, California, 92686, United States
-
University of Kansas
Westwood, Kansas, 66205, United States
-
University of Kentucky
Lexington, Kentucky, 40536, United States
-
University of Louisville
Louisville, Kentucky, 40202, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599-7025, United States
-
University of Tennessee Medical Center
Knoxville, Tennessee, 37920, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22903, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
-
West Virginia University Cancer Center
Morgantown, West Virginia, 26506, United States
-
Yale University
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.